What is the history of Amyotrophic lateral sclerosis ALS?

Amyotrophic lateral sclerosis (ALS) was first described by the French neurologist Jean-Martin Charcot in 1869, who identified the link between the patient’s clinical symptoms and the degeneration of motor neurons in the spinal cord. Since its identification, our understanding of Amyotrophic lateral sclerosis (ALS) has shifted from a purely clinical observation to a complex, multi-faceted disease involving genetic, environmental, and molecular mechanisms.

When and how was Amyotrophic lateral sclerosis (ALS) first identified?

While cases resembling the condition appear in historical medical texts dating back to the early 19th century, Jean-Martin Charcot is credited with the definitive characterization of Amyotrophic lateral sclerosis (ALS) in 1869. Working at the Salpêtrière Hospital in Paris, Charcot meticulously correlated the muscle wasting (amyotrophy) and the hardening (sclerosis) of the lateral columns of the spinal cord observed during autopsies. His work provided the foundation for recognizing the disease as a distinct clinical entity, separating it from other neurological disorders of that era.

How has our understanding of Amyotrophic lateral sclerosis (ALS) evolved?

For much of the 20th century, Amyotrophic lateral sclerosis (ALS) was viewed primarily as a sporadic, fatal motor neuron disorder of unknown origin. The most significant historical shift occurred in the early 1990s with the discovery of the SOD1 gene mutation, which proved that at least a subset of cases had a clear genetic basis. Today, we recognize that Amyotrophic lateral sclerosis (ALS) is a heterogeneous syndrome. We now understand that the disease involves complex protein misfolding, such as the accumulation of TDP-43, and that it exists on a spectrum that can overlap with frontotemporal dementia (FTD).

What are the major milestones in treatment and advocacy?

The history of managing Amyotrophic lateral sclerosis (ALS) is marked by a transition from purely palliative care to targeted therapeutic interventions. Advocacy has played a crucial role in shifting the disease from a "silent" illness to a global research priority. Key milestones include:

• 1939: Baseball legend Lou Gehrig brought international awareness to the disease, leading to it being widely known as "Lou Gehrig's Disease" in the United States.


• 1995: The FDA approved Riluzole, the first medication shown to modestly extend survival in patients with Amyotrophic lateral sclerosis (ALS).


• 2014: The "Ice Bucket Challenge" went viral, raising over $115 million for the ALS Association, which dramatically accelerated global research funding.


• 2017/2022: The approval of Edaravone and later Relyvrio (though subsequently withdrawn) signaled a new era of exploring neuroprotective therapies.

How has modern technology changed the landscape for patients?

Modern genetics has revolutionized our diagnostic approach to Amyotrophic lateral sclerosis (ALS). We now know that approximately 5–10% of cases are familial, while 90% are sporadic. Advanced genomic sequencing allows for the identification of variants in genes like C9orf72, which is the most common genetic cause of the disease. Furthermore, the 333 members of the DiseaseMaps.org community reflect a growing trend of patient-led data sharing, which helps researchers better understand the lived experience and symptom progression of those affected by Amyotrophic lateral sclerosis (ALS) in the modern era.

Next steps

• Consult a board-certified neurologist specializing in neuromuscular disorders or an ALS multidisciplinary clinic.


• Speak with a genetic counselor to discuss the implications of genetic testing for you and your family.


• Join the DiseaseMaps.org community to connect with others who understand the journey of living with this condition.


• Explore clinical trial databases such as ClinicalTrials.gov to stay informed about the latest research and experimental therapies.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Amyotrophic Lateral Sclerosis.


• Orphanet: Amyotrophic Lateral Sclerosis (ORPHA:803).


• OMIM (Online Mendelian Inheritance in Man): Amyotrophic Lateral Sclerosis 1 (ALS1).


• The ALS Association: History of ALS.